Legislation that would expand the FDA's accelerated-approval process for drugs could spur innovation by encouraging investment, biotech editor Luke Timmerman writes. Passage would boost investor confidence in biotech, said Alnylam Pharmaceuticals CEO John Maraganore, and investors are more likely to look favorably on drug candidates that have a shorter, less expensive approval process.

Full Story:

Related Summaries